ES2187047T3 - Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular. - Google Patents

Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.

Info

Publication number
ES2187047T3
ES2187047T3 ES98938555T ES98938555T ES2187047T3 ES 2187047 T3 ES2187047 T3 ES 2187047T3 ES 98938555 T ES98938555 T ES 98938555T ES 98938555 T ES98938555 T ES 98938555T ES 2187047 T3 ES2187047 T3 ES 2187047T3
Authority
ES
Spain
Prior art keywords
dna
composition
animal
regulation
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98938555T
Other languages
English (en)
Spanish (es)
Inventor
Nigel C Phillips
Mario C Filion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Telesta Therapeutics Inc
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ES2187047T3 publication Critical patent/ES2187047T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES98938555T 1997-08-05 1998-08-05 Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular. Expired - Lifetime ES2187047T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5477797P 1997-08-05 1997-08-05
US7506798P 1998-02-18 1998-02-18
US7511198P 1998-02-18 1998-02-18
US8631798P 1998-05-21 1998-05-21

Publications (1)

Publication Number Publication Date
ES2187047T3 true ES2187047T3 (es) 2003-05-16

Family

ID=27489673

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98938555T Expired - Lifetime ES2187047T3 (es) 1997-08-05 1998-08-05 Composicion y metodo para la regulacion de la proliferacion celular y la muerte celular.

Country Status (17)

Country Link
US (2) US6329347B1 (enExample)
EP (1) EP1003525B1 (enExample)
JP (2) JP4335435B2 (enExample)
KR (1) KR100533576B1 (enExample)
AT (1) ATE227996T1 (enExample)
AU (1) AU736450B2 (enExample)
BR (1) BR9815602A (enExample)
CA (1) CA2299548C (enExample)
DE (1) DE69809561T2 (enExample)
DK (1) DK1003525T3 (enExample)
ES (1) ES2187047T3 (enExample)
HU (1) HU227921B1 (enExample)
IL (3) IL134371A0 (enExample)
NO (1) NO322450B1 (enExample)
NZ (1) NZ502674A (enExample)
PT (1) PT1003525E (enExample)
WO (1) WO1999007383A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법
NZ506406A (en) * 1998-02-18 2002-11-26 Bioniche Life Sciences Inc Compositions comprising Mycobacterium phlei DNA and methods for its use in the treatment of bladder cancer
WO2000033875A1 (en) * 1998-12-04 2000-06-15 Bioniche Life Sciences Inc. Chemotherapeutic composition and method
DK1135164T3 (da) * 1998-12-04 2004-12-20 Bioniche Life Sciences Inc Sammensætning til behandling af inflammation
US6809081B1 (en) * 1998-12-04 2004-10-26 Bioniche Life Sciences, Inc. Chemotherapeutic composition and method
WO2000059518A2 (en) * 1999-04-01 2000-10-12 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
US6794368B1 (en) 1999-04-01 2004-09-21 Bioniche Life Sciences Inc. Composition and method for inducing apoptosis in prostate cancer cells
PT1181304E (pt) 1999-04-08 2008-01-23 Antisoma Res Ltd Actividade antiproliferativa de oligonucleótidos ricos em g e método de utilização dos mesmos para ligação a nucleolina
WO2001022979A1 (en) * 1999-09-29 2001-04-05 Bioniche Life Sciences Inc. Method to disrupt mitochondrial function
DE60036019T2 (de) * 1999-12-13 2008-05-29 Bioniche Life Sciences Inc., Belleville Synthetische oligonukleotide die therapeutisch nützlich sind
US7125858B2 (en) * 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US20030044352A1 (en) * 2001-04-24 2003-03-06 Phillips Nigel C. Method for evaluating the efficacy of treatment with bacterial DNA and bacterial cell walls
US6673566B1 (en) 2002-01-10 2004-01-06 The United States Of America As Represented By The Secretary Of Agriculture Diagnosis of pathogen infections through analysis of nitrite production by antigen stimulated leukocytes
CN103169984B (zh) * 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
WO2012049654A1 (en) * 2010-10-13 2012-04-19 Bioniche Life Sciences, Inc. Bacterial ribonucleic acid cell wall compositions and methods of making and using them

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172815A (en) 1962-04-24 1965-03-09 Warner Lambert Pharmaceutical Method for preparing reticulo-endo-thelial system stimulant and stimulant thereof
US4152423A (en) 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
FR2160326B1 (enExample) 1971-11-19 1975-02-07 Anvar
CA1020460A (en) 1973-02-23 1977-11-08 Wellcome Foundation Limited (The) Isolation of immunostimulating glycopeptide from bacteria
US3976544A (en) 1973-06-19 1976-08-24 The Agence Nationale De Valorisation De Le Recherche Water-soluble immunological adjuvants, in particular for vaccines, obtained from mycobacteria and related microorganisms and process for their extraction
FR2374042A1 (fr) 1976-06-04 1978-07-13 Merieux Inst Nouveau medicament immunostimulant et son procede de preparation
JPS54140710A (en) 1978-03-10 1979-11-01 Mitsui Toatsu Chem Inc Anti-tumor substance and its preparation
DE3011461C2 (de) 1980-03-25 1986-10-30 Dr. Madaus & Co, 5000 Köln Verwendung von Propionibakterien
US4520019A (en) 1982-04-29 1985-05-28 Ribi Immunochem Research, Inc. Stable composition and preparation thereof
US4579941A (en) 1982-08-13 1986-04-01 Mitsuitoatsu Chemicals, Inc. Thermally-denatured deoxyribonucleic acid MD-011 and antitumor agent
US4663306A (en) 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
US4744984A (en) 1985-10-08 1988-05-17 Vetrepharm Research, Inc. Antiviral immunotherapeutic agent and preparation thereof
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
AU691797B2 (en) 1993-01-29 1998-05-28 Vetrepharm, Inc. Immunotherapeutic composition
KR100533576B1 (ko) 1997-08-05 2005-12-05 바이오니취 라이프 사이언시즈 인코포레이티드 세포증식 및 세포사멸 조절용 조성물 및 방법

Also Published As

Publication number Publication date
NO20000576D0 (no) 2000-02-04
AU8723698A (en) 1999-03-01
BR9815602A (pt) 2001-12-11
IL134371A0 (en) 2001-04-30
JP4335435B2 (ja) 2009-09-30
DE69809561D1 (de) 2003-01-02
IL134371A (en) 2007-07-24
JP2001513504A (ja) 2001-09-04
IL180924A (en) 2010-11-30
IL180924A0 (en) 2007-07-04
PT1003525E (pt) 2003-03-31
EP1003525A1 (en) 2000-05-31
HUP0003012A3 (en) 2004-03-29
EP1003525B1 (en) 2002-11-20
DE69809561T2 (de) 2003-09-25
AU736450B2 (en) 2001-07-26
JP2008208140A (ja) 2008-09-11
HUP0003012A2 (hu) 2000-12-28
HU227921B1 (hu) 2012-06-28
WO1999007383A1 (en) 1999-02-18
CA2299548C (en) 2009-12-29
US6326357B1 (en) 2001-12-04
KR20010022643A (ko) 2001-03-26
NO20000576L (no) 2000-04-04
KR100533576B1 (ko) 2005-12-05
WO1999007383B1 (en) 1999-03-25
NO322450B1 (no) 2006-10-09
US6329347B1 (en) 2001-12-11
DK1003525T3 (da) 2003-03-24
NZ502674A (en) 2002-06-28
CA2299548A1 (en) 1999-02-18
ATE227996T1 (de) 2002-12-15

Similar Documents

Publication Publication Date Title
BRPI0412845A (pt) herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo
CY1119742T1 (el) Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
TR200002355T2 (tr) 2-(Pürin-9-il)tetrahidrofüran-3,4-diol türevleri
ES2191192T3 (es) Tienopirimidinas.
BR9808068A (pt) Processo in vitro para eliminar células tumorosas de uma população de células que inclui células não-tumorosas, para enriquecerr o número de células germinativas numa população de células hematopoéticas, para preparar células hematopoéticas isoladas para reintrodução num paciente, para a eliminação de uma primeira população de células de uma segunda população de células, e, processo de eliminação de células tumorosas de uma população de células que inclui células não-tumorosas
MX9205988A (es) Nucleosidos biciclicos, oligonucleotidos, procedimiento para su preparacion y productos intermedios.
IL180924A0 (en) Method for regulating cell proliferation and cell death
ES2162284T3 (es) Proceso para la fabricacion de tensioactivos que contienen grupos alquilo de cadena ramificada.
ES2196181T3 (es) Derivados de purina y proceso para su preparacion.
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
EP1411118A4 (en) Cell proliferation inhibitors with anti-glycanic-3 antibody
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
ES2193145T3 (es) Proteinas procoagulants quimericas.
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
NO331101B1 (no) In vitro-fremgangsmate for a uttrykke et antigenmolekyl og antigenmolekyl og et fotosensibiliserende middel for anvendelse ved uttrykking av antigenmolekylet.
PE20010694A1 (es) Plasmido autonomamente reproducible en bacterias corineformes
CO5011082A1 (es) Formulacion medicamentosa con liberacion controlada de sus- tancia activa
DK1900811T3 (da) Berigede cellepopulationer i centralnervesystemet
CY1105439T1 (el) Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση
Kashket et al. Accumulation of methylglyoxal in the gingival crevicular fluid of chronic periodontitis patients
DE69732857D1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
ES2169995B1 (es) Composicion a base de la proteina lip2a y su uso en la preparacion de un medicamento para suscitar una respuesta inmune contra un antigeno.
BR0208879A (pt) Artigo
ECSP024267A (es) Imidazotriazinonas sustituidas por 2-fenilo